3-carboethoxyphenyltributylstannane | 150356-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-carboethoxyphenyltributylstannane
• 英文别名: ethyl 3-(tributylstannyl)benzoate；ethyl 3-(tri-n-butylstannyl) benzoate
• CAS: 150356-72-2
• 化学式: C₂₁H₃₆O₂Sn
• 分子量: 439.226
• InChiKey: QKNUXWCCOVKWAU-UHFFFAOYSA-N

物化性质

• 沸点：
  445.9±47.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.92
• 重原子数：
  24
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-甲酰基-6-甲氧基苯基)三氟甲磺酸酯 、 3-carboethoxyphenyltributylstannane 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.75h， 以94%的产率得到2-methoxy-3'-carboethoxy-[1,1'-biphenyl]-6-carboxaldehyde
  参考文献：
  名称：

  Biaryl diacid inhibitors of human s-PLA 2 with anti-inflammatory activity

  摘要：

  Twenty-four hydrophobic dicarboxylic acids are described which were evaluated as inhibitors of 14 kDa human platelet phospholipase A(2) (HP-PLA(2)). In general, biarylacetic acid derivatives were found to be more active than biaryl acids or biaryl-propanoic acids. More potent inhibitors were obtained when hydrophobic groups were attached to the biaryl acid nucleus using an olefin linkage as compared to an ether linkage. Compounds with larger hydrophobic groups were usually more potent inhibitors of HP-PLA(2). Five of the compounds disclosed in this report (2, 4, 28, 36b and 36i) were found to possess significant anti-inflammatory activity in a phorbol ester induced mouse ear edema model of chronic inflammation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00047-x
• 作为产物：
  描述：

  3-溴苯甲酸乙酯 、 六正丁基二锡 在 palladium diacetate 、 三环己基膦 作用下， 以 neat (no solvent) 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以81%的产率得到3-carboethoxyphenyltributylstannane
  参考文献：
  名称：

  在无溶剂条件下芳基卤化物的甲氨酰化、Stille 交叉偶联和一锅两步甲氨酰化/Stille 交叉偶联反应

  摘要：

  首次报道了钯催化芳基卤化物、Stille 交叉偶联和一锅两步 stannylation/Stille 交叉偶联 (SSC) 的无溶剂协议。带有受体、供体以及空间要求的取代基的（杂）芳基卤化物以高产率被甲锡烷基化和/或偶联。该反应在空气中由常规的乙酸钯 (II)/PCy3 (Pd(OAc)2/PCy3) 催化，使用可用的碱 CsF，并且不使用高纯度试剂。开发的合成程序用途广泛、稳健且易于扩展。没有溶剂，并消除了芳基锡烷的分离程序，使 SSC 协议简单、步骤经济且高效，用于通过一锅两步程序合成联芳。

  DOI：

  10.1002/ejoc.201701463

文献信息

• Biaryl phospholipase A.sub.2 inhibitors
  申请人：Bristol-Myers Squibb

  公开号：US05391817A1

  公开（公告）日：1995-02-21

  Certain novel biaryl compounds are effective phospholipase A.sub.2 (PLA.sub.2) inhibitors.

  某些新型联苯化合物是有效的磷脂酶A.sub.2（PLA.sub.2）抑制剂。
• Pyridine compounds which are useful as angiotensin II receptor
  申请人：Imperial Chemical Industries PLC

  公开号：US05236936A1

  公开（公告）日：1993-08-17

  The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

  本发明涉及公式I的具有药用价值的化合物，其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，R.sup.6，R.sup.7，X和Z具有本文中定义的各种含义，以及它们的非毒性盐和含有它们的制药组合物。这些新型化合物在治疗高血压和充血性心力衰竭等疾病方面具有价值。本发明还涉及制造这些新型化合物的工艺以及将这些化合物用于医疗治疗的用途。
• Endothelin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20020002177A1

  公开（公告）日：2002-01-03

  Novel indane and indene derivatives are described which are endothelin receptor antagonists.

  本文描述了一种新型的吲哚烷和吲哚烯衍生物，它们是内皮素受体拮抗剂。
• Endothelin receptor anatagonists
  申请人：SmithKline Beecham Corporation

  公开号：US05719182A1

  公开（公告）日：1998-02-17

  Novel indane and indene derivatives are described which are endothelin receptor antagonists.

  本文描述了一种新的吲哚烷和吲哚烯衍生物，它们是内皮素受体拮抗剂。
• Tosylates in palladium-catalysed coupling reactions. Application to the synthesis of arylcoumarin inhibitors of gyrase B
  作者：Laurent Schio、Fabienne Chatreaux、Michel Klich

  DOI：10.1016/s0040-4039(99)02351-5

  日期：2000.3

  The palladium-catalysed coupling reaction between tosylate derivatives and organostannanes has been investigated as a methodology for carbon-carbon bond formation. Aryl substituents have been successfully incorporated even in highly functionalised coumarin structures to afford new analogues of the antibiotic novobiocin. (C) 2000 Elsevier Science Ltd. All rights reserved.